Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton.

No abstract is available for this paper.

• Publication year

  1985

• Venue

  Journal of Urology

• Publication date

  1985-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0022-5347(17)47663-4PMID 2932559
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatitein vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats

  2005cited by this paper
• Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton.

  1983cited by this paper
• Use of dichloromethylene diphosphonate in metastatic bone disease.

  1983cited by this paper
• Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia.

  1983cited by this paper
• Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.

  1983cited by this paper
• Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma.

  1980cited by this paper
• Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.

  1980cited by this paper
• Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

  1979cited by this paper
• Ethane-1-hydroxy-1,1-diphosphonate (EHDP) effects on incorporation and accumulation of osteoclast nuclei

  1977cited by this paper
• Mechanisms of bone destruction in the development of skeletal metastases

  1976cited by this paper
• Letter: Green-tobacco sickness.

  1975cited by this paper
• Evidence for the secretion of an osteoclast stimulating factor in myeloma.

  1974cited by this paper
• Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats

  1973cited by this paper
• Skeletal renewal and metabolic bone disease.

  1969cited by this paper
• Diphosphonates Inhibit Formation of Calcium Phosphate Crystals in vitro and Pathological Calcification in vivo

  1969cited by this paper
• Skeletal renewal and metabolic bone disease.

  1969cited by this paper
• Skeletal renewal and metabolic bone disease.

  1969cited by this paper
• METHODS FOR THE EARLY RECOGNITION OF COR PULMONALE.

  1964cited by this paper
• IMMUNISATION AGAINST MEASLES.

  1964cited by this paper

• Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions.

  2019cites this paper
• Zoledronic acid for the treatment of prostate cancer

  2019cites this paper
• بیسفسفوناتها در درمان سرطان پیشرفته پروستات

  2017cites this paper
• Bisphosphonates for advanced prostate cancer.

  2017cites this paper
• Bone-directed therapy in prostate cancer: Rationale and novel approaches

  2016cites this paper
• Chapter 1. General introduction

  2015cites this paper
• Clodronate: new directions of use.

  2015cites this paper
• Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis.

  2013cites this paper
• Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.

  2013cites this paper
• Improved Efficacy of Intramuscular Weekly Administration of Clodronate 200 mg (100 mg Twice Weekly) Compared with 100 mg (Once Weekly) for Increasing Bone Mineral Density in Postmenopausal Osteoporosis

  2013cites this paper
• The Clinical and Cost Considerations of Bisphosphonates in Preventing Bone Complications in Patients with Metastatic Breast Cancer or Multiple Myeloma

  2012cites this paper
• Bone-targeted therapy in metastatic prostate cancer: osteoclast inhibitors and bone-seeking radiopharmaceuticals

  2010cites this paper
• Burden of metastatic bone disease from genitourinary malignancies

  2010cites this paper
• Clodronic Acid Formulations Available in Europe and their Use in Osteoporosis

  2009cites this paper
• Clinical value of bisphosphonates in cancer therapy.

  2007cites this paper
• Cementless CUT femoral neck prosthesis: increased rate of aseptic loosening after 5 years.

  2007cites this paper
• Incadronate induces cell detachment and apoptosis in prostatic PC-3 cells.

  2007cites this paper
• Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open‐label controlled study

  2007cites this paper
• Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells.

  2006cites this paper
• Bisphosphonates for advanced prostate cancer.

  2006cites this paper
• Calcitonin

  2006cites this paper
• Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells.

  2006cites this paper
• Bisphosphonates Treatment in Metastatic Prostate Cancer

  2005cites this paper
• Three-dimensional trabecular bone architecture of the lumbar spine in bone metastasis from prostate cancer: comparison with degenerative sclerosis

  2005cites this paper
• Intermittent intramuscular clodronate therapy: a valuable option for older osteoporotic women.

  2005cites this paper
• Targeted radionuclide therapy for bone metastases

  2005cites this paper
• A tolerability andpharmacokinetic study of a newinjectable formulation of disodium clodronate in healthyfemale volunteers

  2004cites this paper
• The emerging role of bisphosphonates in prostate cancer.

  2004cites this paper
• Advances in the use of bisphosphonates in the prostate cancer setting

  2004cites this paper
• Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients

  2004cites this paper
• Advances in the use of bisphosphonates in the prostate cancer setting

  2004cites this paper
• Costs of prostate cancer, metastatic to the bone, in the Netherlands.

  2003cites this paper
• Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment.

  2003cites this paper
• Bisphosphonate therapy in the oncology setting

  2003cites this paper
• Management of Metastatic Bone Disease and Hypercalcemia of Malignancy

  2003cites this paper
• Therapeutic benefit of bisphosphonates in the management of prostate cancer-related bone disease

  2003cites this paper
• Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.

  2003cites this paper
• Clodronate for treatment of bone metastases in hormone refractory prostate cancer.

  2003cites this paper
• Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer.

  2003cites this paper
• The role of bisphosphonates in the management of metastatic prostate cancer

  2003cites this paper
• Bisphosphonates in the Management of Metastatic Prostate Cancer

  2003cites this paper
• Role of bisphosphonates in prostate cancer bone metastases.

  2003cites this paper
• Safety of subcutaneous clodronate and efficacy in hypercalcemia of malignancy: a novel route of administration.

  2003cites this paper
• Chapter 46 – Androgen-independent Prostate Cancer: The Evolving Role of Chemotherapy

  2003cites this paper
• A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

  2003cites this paper
• EFFECTS OF LONG-TERM CLODRONATE ADMINISTRATION ON BONE AND ON FRACTURE HEALING IN RAT , WITH SPECIAL REFERENCE TO METHODOLOGICAL ASPECTS ANTTI KOIVUKANGAS

  2002cites this paper
• The antitumor potential of bisphosphonates.

  2002cites this paper
• The New Bisphosphonate, Zometa® (Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate

  2002influential citation
• Effects of long-term clodronate administration on bone and on fracture healing in rat, with special reference to methodological aspects

  2002cites this paper
• The use of bisphosphonates in the management of bone metastatic prostate cancer

  2002cites this paper
• Bisphosphonates: their evolving role in the management of prostate cancer-related bone disease

  2002cites this paper
• A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

  2002cites this paper
• Molecular Evidence-Based Use of Bone Resorption-Targeted Therapy in Prostate Cancer Patients at High Risk for Bone Involvement

  2002cites this paper
• Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.

  2002cites this paper
• The potential role of bisphosphonates in prostate cancer

  2002cites this paper
• Mechanisms of Bisphosphonate Effects on Osteoclasts, Tumor Cell Growth, and Metastasis

  2002cites this paper
• Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.

  2002cites this paper
• Antimetastatic drugs in prostate cancer.

  2002cites this paper
• Ibandronate in the treatment of prostate cancer associated painful osseous metastases

  2002cites this paper
• Transient relief of metastatic cancer bone pain by oral administration of etidronate

  2002cites this paper
• Therapy of metastatic bone pain.

  2001cites this paper
• Complementary and alternative therapies for advanced prostate cancer.

  2001cites this paper
• Strategies for Management of Prostate Cancer-Related Bone Pain

  2001cites this paper
• Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.

  2001cites this paper
• The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer.

  2001cites this paper
• The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates.

  2001cites this paper
• [Biphosphonates in the treatment of bone metastasis of prostatic cancer].

  2001cites this paper
• Oral bisphosphonates

  2000cites this paper
• Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton

  2000cites this paper
• Markers of bone turnover for the management of patients with bone metastases from prostate cancer

  2000cites this paper
• Intramuscular clodronate therapy in postmenopausal osteoporosis.

  1999cites this paper
• Clodronate in the management of bone metastases: a clinical study of 91 patients.

  1999cites this paper
• Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton.

  1998cites this paper
• Markers of bone resorption in patients treated with pamidronate.

  1998cites this paper
• Systemic bone‐seeking radionuclides for palliation of painful osseous metastases: Current concepts

  1998cites this paper
• Skeletal response to clodronate in prostate cancer with bone metastases.

  1997cites this paper
• Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer.

  1997cites this paper
• Bisphosphonates in prostate carcinoma

  1997cites this paper
• The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer.

  1997cites this paper
• Utility of bisphosphonates in treating bone metastases

  1996cites this paper
• Malignant bone pain: pathophysiology and treatment

  1996cites this paper
• Effect of concomitant administration of clodronate and estramustine phosphate on their bioavailability in patients with metastasized prostate cancer.

  1996cites this paper
• Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer.

  1995cites this paper
• Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study.

  1995cites this paper
• Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.

  1995cites this paper
• Consequences of neoplasia induced bone-resorption and the use of clodronate (review).

  1994cites this paper
• Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease.

  1994cites this paper
• Metastatic Bone Disease

  1994cites this paper
• Bisphosphonates: Mechanisms of Actionand Clinical Use in Hypercalcemia of Malignancy and Tumor-Induced Bone Destruction

  1994cites this paper
• The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study.

  1994cites this paper
• Clodronate

  1994influential citation
• Radionuclide therapy of bone metastases: prospects for enhancement of therapeutic efficacy.

  1993cites this paper
• [Bone pain of metastatic origin].

  1993cites this paper
• Bisphosphonates: Mechanisms of Action and Clinical Use

  1993cites this paper
• Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group.

  1993cites this paper
• New bisphosphonates in the treatment of bone metastases

  1993cites this paper
• Comparative effects of clodronate and calcitonin on bone in metastatic breast cancer: a histomorphometric study.

  1993cites this paper
• The pharmacological management of cancer pain. Part 1: The role of non opioid and adjuvant drugs.

  1993cites this paper
• Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate.

  1993cites this paper
• [The use of the preparation bonefos in the combined therapy of multiple myeloma patients].

  1993cites this paper